Immunorizon

T-and NK-cell Engagers for Cancer Therapy

Active Acquired Startup Acquired Yavne Founded 2017-12

Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company extends its pipeline and uses tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.